| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HRG3; Neuregulin 3; Nrg3; Pro neuregulin 3;;NRG3 |
| WB Predicted band size | Calculated MW: 78 kDa ; Observed MW: 56 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human NRG3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是模拟的关于NRG3抗体的参考文献示例(仅供示例参考，具体文献需通过学术数据库查询)：
---
1. **文献名称**：*Development and Validation of a Novel NRG3 Antibody for Immunohistochemical Analysis in Human Brain Tissues*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种高特异性的NRG3多克隆抗体，并通过Western blot和免疫组化验证其在人脑组织中的表达。结果显示该抗体能特异性识别NRG3的C端结构域，并成功用于检测发育过程中大脑皮层的NRG3表达变化。
---
2. **文献名称**：*NRG3 Signaling in Breast Cancer: Insights from Antibody-Based Inhibition Studies*
**作者**：Chen L, et al.
**摘要**：通过使用商业化NRG3中和抗体，研究团队探究了NRG3-ErbB4通路在乳腺癌细胞侵袭中的作用。实验表明，阻断NRG3可显著抑制肿瘤细胞迁移，提示其作为潜在治疗靶点的可能性。
---
3. **文献名称**：*Localization of NRG3 in the Murine Nervous System Using a Monoclonal Antibody Approach*
**作者**：Garcia R, et al.
**摘要**：该研究制备了一种抗NRG3的单克隆抗体，并系统分析了NRG3在小鼠中枢及周围神经系统的分布。免疫荧光结果显示NRG3在海马体和背根神经节中高表达，支持其在突触可塑性中的功能假说。
---
4. **文献名称**：*Comparative Analysis of NRG3 Antibody Specificity Across Commercial and Custom Reagents*
**作者**：Wang Y, et al.
**摘要**：文章对比了多种市售及实验室自制的NRG3抗体的特异性与灵敏度，发现部分抗体存在交叉反应问题。通过敲除细胞模型验证，推荐了两种适用于蛋白质印迹和流式细胞术的可靠抗体。
---
**注意**：以上为模拟文献，如需真实数据，请通过PubMed、Web of Science等平台检索关键词“NRG3 antibody”或“Neuregulin 3”。
Neuregulin 3 (NRG3) is a member of the neuregulin family of growth factors, which play critical roles in cell-cell signaling by activating ErbB receptor tyrosine kinases. Structurally, NRG3 contains an epidermal growth factor (EGF)-like domain essential for receptor binding, functioning through paracrine or autocrine mechanisms. It is prominently expressed in the central nervous system, mammary tissue, and heart, influencing neurodevelopment, synaptic plasticity, and cellular differentiation. Dysregulation of NRG3 has been linked to cancers (e.g., breast, ovarian, lung) and neuropsychiatric disorders (e.g., schizophrenia, bipolar disorder), highlighting its dual role as a potential therapeutic target and biomarker.
NRG3 antibodies are vital tools for detecting NRG3 expression and localization in research. Polyclonal or monoclonal antibodies are designed to target specific epitopes, enabling applications like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help elucidate NRG3’s tissue-specific functions, signaling pathways, and interactions with ErbB receptors. However, challenges remain due to NRG3’s splice variants and post-translational modifications, necessitating rigorous validation of antibody specificity. Ongoing studies leverage NRG3 antibodies to explore its therapeutic potential, particularly in oncology and neurobiology, where modulating NRG3-ErbB signaling may offer novel treatment strategies.
×
